The FAIRplus project kicked off in January, with a 2 day meeting of the 22 partners - including The Hyve - from both academia and industry. The project is funded by IMI and aims to improve the data management and governance in European health research, advancing the capability to extract maximum benefit from life science data.
The FAIRplus project has five main goals:
- To establish a value-based process for prioritisation and selection of IMI project databases.
- To develop guidelines, tools and metrics needed to make data Findable, Accessible, Interoperable and Reusable (FAIR).
- To deliver tailored training for data handlers (academia, SMEs and pharmaceuticals).
- To change and sustain the data management culture in pharma, academia and SMEs.
- To organise FAIR Innovation & SME Events to foster an innovation ecosystem on FAIR open data to power future reuse, knowledge generation, and societal benefit.
The FAIRplus partners are very optimistic about the outcomes and impacts of the project. Abel Ureta-Vidal, Chief Product Officer and Founder of Eagle Genomics, one of the Associate Partners of the project said:
"FAIRplus will give us an opportunity to provide feedback on the FAIR methodology and better understand the project outcomes. Translating the FAIR principles into a well-defined FAIR standard will be a great step forward in data discovery, usability and ultimately exposing its relevance and value."
Kees van Bochove, CEO of The Hyve, also shared his belief that the FAIRplus project provides a unique opportunity for The Hyve to bring together a number of key elements that we have been working on for the last few years:
"First, many of the other partners in the projects, both from academia as well as from the EFPIA companies, are long term collaborators that we've been working with on the FAIR principles and also implementing open source technologies such as OHDSI, tranSMART, RDF metadata stores and so on. Second, The Hyve has been involved in quite a few IMI projects, and making the results from these projects FAIR and available for the scientific community inevitably comes up, but is also not without challenges. FAIRplus provides us with an opportunity to address these challenges head on in a repeatable manner, with our FAIR partners, and then showcase it using a number of past and current IMI and other public-private scientific collaboration projects."
Read the official press release here.
Acknowledgement
FAIRplus project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 802750. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA Companies. This communication reflects the views of the authors and neither IMI nor the European Union, EFPIA or any Associated Partners are liable for any use that may be made of the information contained herein.
